First Time Loading...
M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 14.64 PLN -0.41% Market Closed
Updated: May 19, 2024

Intrinsic Value

MOC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. [ Read More ]

The intrinsic value of one MOC stock under the Base Case scenario is 3.95 PLN. Compared to the current market price of 14.64 PLN, Molecure SA is Overvalued by 73%.

Key Points:
MOC Intrinsic Value
Base Case
3.95 PLN
Overvaluation 73%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
Molecure SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MOC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Molecure SA

Provide an overview of the primary business activities
of Molecure SA.

What unique competitive advantages
does Molecure SA hold over its rivals?

What risks and challenges
does Molecure SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecure SA.

Provide P/S
for Molecure SA.

Provide P/E
for Molecure SA.

Provide P/OCF
for Molecure SA.

Provide P/FCFE
for Molecure SA.

Provide P/B
for Molecure SA.

Provide EV/S
for Molecure SA.

Provide EV/GP
for Molecure SA.

Provide EV/EBITDA
for Molecure SA.

Provide EV/EBIT
for Molecure SA.

Provide EV/OCF
for Molecure SA.

Provide EV/FCFF
for Molecure SA.

Provide EV/IC
for Molecure SA.

Show me price targets
for Molecure SA made by professional analysts.

What are the Revenue projections
for Molecure SA?

How accurate were the past Revenue estimates
for Molecure SA?

What are the Net Income projections
for Molecure SA?

How accurate were the past Net Income estimates
for Molecure SA?

What are the EPS projections
for Molecure SA?

How accurate were the past EPS estimates
for Molecure SA?

What are the EBIT projections
for Molecure SA?

How accurate were the past EBIT estimates
for Molecure SA?

Compare the revenue forecasts
for Molecure SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecure SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecure SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecure SA compared to its peers.

Compare the P/E ratios
of Molecure SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecure SA with its peers.

Analyze the financial leverage
of Molecure SA compared to its main competitors.

Show all profitability ratios
for Molecure SA.

Provide ROE
for Molecure SA.

Provide ROA
for Molecure SA.

Provide ROIC
for Molecure SA.

Provide ROCE
for Molecure SA.

Provide Gross Margin
for Molecure SA.

Provide Operating Margin
for Molecure SA.

Provide Net Margin
for Molecure SA.

Provide FCF Margin
for Molecure SA.

Show all solvency ratios
for Molecure SA.

Provide D/E Ratio
for Molecure SA.

Provide D/A Ratio
for Molecure SA.

Provide Interest Coverage Ratio
for Molecure SA.

Provide Altman Z-Score Ratio
for Molecure SA.

Provide Quick Ratio
for Molecure SA.

Provide Current Ratio
for Molecure SA.

Provide Cash Ratio
for Molecure SA.

What is the historical Revenue growth
over the last 5 years for Molecure SA?

What is the historical Net Income growth
over the last 5 years for Molecure SA?

What is the current Free Cash Flow
of Molecure SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Molecure SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Molecure SA

Current Assets 87.3m
Cash & Short-Term Investments 85m
Receivables 829.4k
Other Current Assets 1.5m
Non-Current Assets 88.2m
PP&E 8.6m
Intangibles 79.5m
Current Liabilities 7.8m
Accounts Payable 5.5m
Accrued Liabilities 776.7k
Other Current Liabilities 1.4m
Non-Current Liabilities 3.6m
Long-Term Debt 3.3m
Other Non-Current Liabilities 324k
Efficiency

Earnings Waterfall
Molecure SA

Revenue
1.4m PLN
Cost of Revenue
-1.8m PLN
Gross Profit
-424.5k PLN
Operating Expenses
-21.1m PLN
Operating Income
-21.5m PLN
Other Expenses
4.1m PLN
Net Income
-17.4m PLN

Free Cash Flow Analysis
Molecure SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MOC Profitability Score
Profitability Due Diligence

Molecure SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative Gross Profit
Negative 1-Year Revenue Growth
Negative ROE
27/100
Profitability
Score

Molecure SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

MOC Solvency Score
Solvency Due Diligence

Molecure SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Molecure SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOC Price Targets Summary
Molecure SA

Wall Street analysts forecast MOC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOC is 26.11 PLN with a low forecast of 25.86 PLN and a high forecast of 26.88 PLN.

Lowest
Price Target
25.86 PLN
77% Upside
Average
Price Target
26.11 PLN
78% Upside
Highest
Price Target
26.88 PLN
84% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Molecure SA

Shareholder Return

MOC Price
Molecure SA

1M 1M
+1%
6M 6M
-15%
1Y 1Y
-29%
3Y 3Y
-70%
5Y 5Y
-9%
10Y 10Y
-50%
Annual Price Range
14.64
52w Low
14.22
52w High
23.95
Price Metrics
Average Annual Return 75.24%
Standard Deviation of Annual Returns 235.32%
Max Drawdown -82%
Shares Statistics
Market Capitalization 246.5m PLN
Shares Outstanding 16 836 000
Percentage of Shares Shorted
N/A

MOC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Molecure SA

Country

Poland

Industry

Pharmaceuticals

Market Cap

246.5m PLN

Dividend Yield

0%

Description

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

Contact

WOJ. MAZOWIECKIE
Warsaw
Zwirki i Wigury 101
+48225526724
https://molecure.com/

IPO

2018-04-19

Employees

106

Officers

Co-Founder, CEO & President of Management Board
Mr. Marcin Jan Szumowski Ph.D.
Co-Founder & VP of Research Chemistry
Mr. Adam Golebiowski Ph.D.
CFO & Member of the Management Board
Mr. Slawomir Piotr Broniarek
Chief Scientific Officer & Member of Management Board
Mr. Zbigniew Zaslona
Member of Management Board & HR Director
Ms. Agnieszka Rajczuk-Szczepanska
Co-Founder & Head of Medicinal Chemistry
Mr. Jacek Olczak Ph.D.
Show More
Chief Medical Officer & Member of Management Board
Dr. Samson Fung M.D.
Head of CMC
Ms. Magdalena Tyszkiewicz
Director of the Management Board Office
Ms. Marta Borkowska
Show Less

See Also

Discover More
What is the Intrinsic Value of one MOC stock?

The intrinsic value of one MOC stock under the Base Case scenario is 3.95 PLN.

Is MOC stock undervalued or overvalued?

Compared to the current market price of 14.64 PLN, Molecure SA is Overvalued by 73%.